CMV treatment licensed in US
The US FDA has approved Roche's valgancyclovir (Valcyte) for the treatment of cytomegalovirus retinitis in AIDS patients. It is the oral pro-drug of the company's existing anti-CMV treatment ganciclovir (Cytovene), which is currently the most widely-prescribed anti-CMV drug worldwide.